HK2 and hepatocellular carcinoma: Consistent with our in vitro analysis, Sorafenib non-responders showed high levels of HK2 in contrast to responders, indicating a potential upregulation of glycolysis in Sorafenib-resistant HCC of patients (Fig. 5p).